News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The Bulk Drug Park is expected to attract investment of around Rs. 10,000 crore and provide employment to more than 20,000 people
-0001_256_384.jpg){kind=logo}
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
The inspection concluded with no observation (FDA-483) issued.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Subscribe To Our Newsletter & Stay Updated
